Introduction
It does not take a great deal of imagination to be able to understand and accept that the diagnosis of malignancy is a difficult one for a patient to come to terms with. The bleak description of prognosis and candid elaboration of outlook given by today's doctors can take away from hope. The patient enters a dark world where survival chances are described in percentages, and the words 'might', 'probable' and 'possible' become part of a personal vocabulary that is all-consuming and overwhelming. In this context, where allopathic doctors cannot provide the certainty of cure for their patients, it is hardly surprising that those patients will turn to other treatment systems. In the situation where hope is lost, how can a patient be considered to be irrational when they seek treatments that do provide hope? Where is the blame and what is the loss to the patient in turning to such treatments for support?
Complementary therapy is big business. It is estimated that the annual spend on alternative health treatments in the UK has reached £4.5 billion. The NHS currently funds this area to the tune of £500 million; this is cause for thought in the current era of rationing of effective anti-cancer treatments.
The novelist and critic, Susan Sontag, has written about the individual's need for support in Illness as a Metaphor and AIDS as its Metaphor.
1,2 To paraphrase her words, she compares the mysteries of the origins of cancers which we face today as having their parallels in the mysteries of tuberculosis that faced patients and clinicians in the 19th century. Sontag considers the similarities between the cures pursued by tuberculosis patients and those undertaken by today's cancer patients. Tuberculosis used to be thought of as a disease that was caused by an excess of black humour. It was believed that there were dietary or psychological bases for the disorder. Tuberculosis patients took bizarre 'cures' and diets, just as do today's cancer patients. And then, remarkably, Koch discovered the tubercle bacillus and, with that discovery, the smoke cleared and the mirrors shattered.
Given this background and the current popularity of complementary and alternative medicines (CAM), we have looked at the existing studies of the use of these agents in cancer. It is surprising to note that there is very little published in this area. For example, one group of authors who carried out a systematic summary of work published between 1999 and 2006 found only 32 studies of CAM published in the North American literature. 3 Most of the additional literature consists of reviews and opinion pieces. Remarkably, we find only one recent survey of the use of CAM in British cancer patients. 4 For this reason, we have examined CAM use in oncology clinical practice in a teaching hospital environment. The objective of this study is to determine patients' pattern of use of complementary and alternative medical therapies, and to canvass their views on the relative values and merits of allopathic and alternative medicine.
Methods
Self-completion questionnaires were distributed to all registered patients attending medical and clinical oncology outpatients department at the Hammersmith and Charing Cross Hospitals, London, from January to December 2007. Completion of questionnaires was entirely voluntary. The questionnaires consisted of 20 questions to determine the incidence and nature of CAM use amongst cancer patients, motivation for taking alternative medicines, opinions on the effectiveness of CAM and views on their doctor-patient relationship. Response categories for most questions were 'Yes/No', but for three questions there was a numerical rating scale of a proposed statement (from 1 = strongly disagree to 5 = strongly agree).
Collection of forms was stopped once 200 correctly completed questionnaires had been returned. Details of age, diagnosis and duration of attendance were obtained from medical records. An unpaired t-test with Welch's correction was employed to assess the difference between patients who had taken CAM, and those who had not (using GraphPad Prism version 3.0 for Windows, GraphPad Software, San Diego, CA, USA). CAMs were defined as any medicine, vitamin supplement or food supplement not prescribed by an allopathic doctor.
Results

Sample demographics
Two hundred completed questionnaires were analysed. Sixty-four percent (n = 127) of respondents were female (Table 1 ). All the major cancer types are present including prostate, breast, lung, colorectal and ovarian cancer (Table 1) . Some patient groups, for example ovarian cancer patients, were more reliable in returning their forms which explains their over-representation and the female bias in the sample population.
There was a wide range of age groups represented with a bias towards older (>60 years) patients as would be expected in an oncology department. Newly diagnosed patients through to long-term follow up cases are fairly evenly distributed through our sample population.
Use of CAM
Twenty-two percent (n = 44) of patients used CAM ( Table 1 ). The majority of these did so independently of professional guidance as only one-third (n = 15) had consulted a CAM therapist, although a further 10% planned to do so in the near future ( Table 2) . As expected, very few of those who did not use CAM had consulted a CAM therapist (6%). Nearly all consultations with CAM therapists had occurred in the UK with only three patients having sought advice from abroad.
Demographics of CAM users compared to non-users
Although there was a female preponderance in the sample population (64% of patients), there was a further higher representation of women amongst CAM users (75%) as compared with non-users (60%) ( Table 1 ). There was a higher proportion of older patients (>70 years) in the CAM non-user group and generally more patients under 60 years old in the CAM user population (Figure 1 ).
There was a non-significant difference in the tumour types represented between the CAM user and non-user groups. There was an increase in the relative number of patients with ovarian cancer in CAM users (34 vs. 28%); however this did not reach statistical significance (P = 0.93) ( Table 1 and Figure 2 ). Differences in the numbers of the rarer tumour types, for example cholangiocarcinoma, were too small to be of significance. There was no significant difference in duration of attendance to clinic with respect to CAM use (P = 0.85).
Other changes to lifestyle and reasons for CAM use
Patients who took CAM did so whilst receiving active treatment (57% of cases- Table 3 ) and during (9) 4 (9) 13 follow-up (43%). Almost half of CAM users had instigated changes in their diet (Table 2) , whereas only 15% of CAM non-users had done so. The changes adopted varied widely but the most common were dairy free or vegetarian diets.
Patients took CAM for a number of reasons but the commonest were the hope that it would make them feel better (31 patients-Table 3), that it had been recommended to them (a total of 29 patients) and that it would help with their cancer (20 patients). Very few patients took CAM because they thought it would make them live longer, because it was safer than conventional medicine or because they thought there was more experience with CAM.
Effectiveness of CAM
Despite taking CAM, the majority of patients (61%) thought there was more evidence behind the use of conventional medicine then CAM (9%), although one-third of patients felt unable to comment (Table 3) . In a separate question, only one patient thought that CAM would cure them whereas almost two-thirds of respondents thought that conventional medicine would do so. Eleven patients (25%) did not answer the question, perhaps reflecting those in whom the disease was in fact incurable. Although 41% of patients using CAM noticed effects on their health, one-third did not and a further quarter felt unable to answer.
Trust
CAM users do not appear to be dissatisfied with the pharmaceutical industry, the medical profession or the treatment they have received. Trust in the medical profession was high with 82% scoring their oncologist 4/5 or 5/5 for trust, and only one patient trusting their doctor very little (Table 3 and Figure 3 ). Only two patients took CAM because they were unhappy with their oncologist (Table 3) . Trust in CAM therapists was significantly lower with only one patient scoring their practitioner 5/5 and the majority scoring them 3/5 (18%) or 4/5 (16%), although there was a high proportion of patients who did not know or did not answer. Compared with non-users, CAM users did not think that drug companies unduly influence doctors' prescriptions although the difference did not reach statistical significance (P = 0.96) (Figure 4 ). Trust in conventional medicine extended to the therapies themselves with 82% of CAM users trusting conventional medicine more than CAM (11%). Those that trusted CAM more did so based on information of its benefit obtained either from the Internet or their CAM practitioner (Table 3) .
CAM users do not conceal their use of complementary therapies with only 27% of respondents thinking that their oncologist was unaware of this. This reflects the finding that very few patients (5% of users and 7% of non-users) felt that physicians disapproved of CAM (P = 0.92).
CAM use
A wide range of CAM was used ( Table 4 ). The most frequently used (24 patients) were multivitamin formulations. Selenium, Omega-3 preparations and homeopathy were also popular choices. Other therapies include some surprising choices such as arsenic, gallium and sulphur, as well as better known treatments like glucosamine, anti-oxidants and ginseng extract.
Patients usually spend comparatively modest amounts of money on their CAM, seldom more than £100 in total ( Table 3 ). The therapies were obtained from CAM therapists, health food shops, by mail order and, less frequently, pharmacies. Few people ordered their supplies from the Internet. Most CAM users thought that complementary medicine should be available through the NHS but a significant minority, 18%, thought not. Only a quarter of patients had been given information about possible interactions between CAM and their prescribed medications.
Discussion
This study of complementary and alternative medical therapies (CAM) has surveyed a group of 200 patients attending oncology outpatients' department. In the sample population there was a broad spectrum of cancer types, a wide variation in age with an expected bias towards the older patient and a relatively equal sex distribution. There is a wide range of treatment available to patients from nonconventional sources ranging from pet therapy, diet and homeopathy to alternative medical systems such as ayurvedic medicine, acupuncture and voodoo. [5] [6] [7] [8] [9] In the context of the widespread publicity around CAMs and diet, we were surprised that just 22% of British cancer patients resorted to supplementation of their conventional treatments. This contrasts with the situation in the USA. A systematic summary of 32 North American studies published between 1999 and 2006 found that between 64% and 81% of cancer survivors used any supplements or vitamins. 3 The use of dietary supplements in the general population of the USA is estimated to be >50%, 3 perhaps explaining the overall higher incidence of CAM use in American cancer patients. In the few European surveys published, we find just 30% of patients using complementary and alternative medical treatments. 10, 11 Female patients were more likely to use CAM than male patients, and younger patients were more likely to try complementary medicine than those over 70 years old. Some studies of American patients with colorectal or lung cancer have reported similar associations between CAM use and female sex, whilst those involving breast, colorectal, lung and prostate cancer report a correlation with younger age. 3 However, surveys focusing on the general cancer population have failed to demonstrate consistent trends with respect to either age or sex.
In our study, we investigated the reasons behind patients' decisions to try CAM. Patients feel that complementary medicine will make them feel better or will help with their cancer. This is in keeping with results from previous reports. 4 Some studies have found a correlation between CAM use, more advanced disease and more pronounced symptoms, however, others have not found this to be the case. 3 Paradoxically, the patients' belief that CAM will make them feel better or will help with their cancer is not backed by a conviction that complementary medicine will be effective, since few thought that there was more evidence for its use than conventional treatments. Indeed, CAM users trusted conventional medicine more than complementary medicine and only 41% had noticed any effect on their health. One might ask why it is that patients persist in taking medications that they feel are unlikely to be curative.
Only one person in our study felt that CAM was more likely effect a cure of their condition, and this contrasts with the findings of another study of CAM in the UK. 4 This is perhaps reassuring as it is known that alternative therapies as a primary treatment for cancer are associated with an increased risk of disease recurrence and death. 12 It is unclear whether the addition of CAM to conventional treatment is beneficial or harmful. Vitamin supplements can be helpful in improving nutritional status in patients who cannot manage a full, balanced diet. This is pertinent because in this study almost half of CAM users and a fifth of all cancer patients instigated changes in their diet as a result of developing cancer, the majority of these being to a dairy free, vegetarian or vegan diet. One study of small cell lung cancer patients has suggested a 35% improvement in survival in those who took vitamin and mineral supplements compared to those who did not. 13 However, a review of the literature has found no evidence of clinical efficacy of homeopathic therapy in cancer care. 14 More worryingly, there is concern that the effects CAM are detrimental. Folic acid has been implicated in the development of cancer and the progression of pre-malignant polyps. 15 St John's Wort is known to induce the cytochrome P450 isozyme CYP3A4, and increases the clearance of drugs metabolized by this enzyme. 16 Meanwhile, dietary supplementation with a-tocopherol, one of the Vitamin E isoforms, was associated with higher rates of recurrence and secondary cancers in patients treated with radiotherapy for head and neck cancer. 17 Anti-oxidants have been suggested to reduce the efficacy of both chemotherapy and radiotherapy by blocking the generation of reactive oxygen species, although the significance of this is the treatment of patients with cancer has yet to be shown. 3 Given the evidence for harmful interactions between CAM and conventional therapies and that at least 57% of respondent were actively receiving anti-cancer treatment, it is worrying that only a minority of patients taking complementary therapy knew about these potential problems. This may reflect that most of those taking CAM (66%) had done so without consulting a CAM practitioner who, it is hoped, would have counselled them accordingly. The onus is also on the physician to advise patients about interactions, yet only 45% of patients had advised their oncologist about their complementary medicine use. The reasons for this may partly be that doctors do not ask for information, as well as fear of physician indifference or opposition. 18 However, the latter seems unlikely here as 30% of CAM users felt that their clinicians were accepting of complementary medicine and just 10% thought that their oncologists had negative views. Improved understanding by oncologists of CAM benefits and risks would surely foster better communication with the patient about this subject and would reduce the risk of adverse interactions.
Very few patients resort to CAM because they were unhappy with their doctor or treatment. Instead CAM was viewed as a useful addition to prescribed treatments, not as an indicator of dissatisfaction, lack of confidence or mistrust of the medical profession. Patients who used CAM trusted their doctor highly and-in fact-significantly more than their CAM therapist. This is reflected in other studies since only one of these, involving breast cancer survivors in rural America, has found that CAM use was associated with dissatisfaction with their physician. 19 The amount of money spent on CAM ranged significantly from less than £10 to more than £500 with a median spend ranging between £50 and £100. Reflecting this significant financial outlay, the majority of patients felt that complementary medicine should be available on the NHS.
This study has surveyed 200 oncology outpatients patients for their habits and views regarding CAM. Given the broad range of age, diagnoses, duration of attendance, and racial heterogeneity of the hospital catchment areas (data not shown) the results found here are likely to be applicable to the UK cancer patient population in general. However, there are limitations to the study. The questionnaires were self-completion and entirely voluntary and so self-selection bias is an issue since better motivated and more involved patients, those that one might think are more likely to use CAM, are likely to be over-represented in the sample population.
So it would seem that complementary and alternative medical treatments are relatively infrequently used by oncology patients in an urban British environment. Those that choose CAM do so not as an indication of dissatisfaction or lack of faith in their oncologist or in conventional cancer medicine but, on the whole, to make the patient feel better. They are realistic about the effectiveness of CAM because although they hope it will help with the treatment of their cancer, they actually place their trust and belief in conventional medicine. Physicians should therefore not feel threatened or disparaged by patients pursuing complementary therapies. Instead, by understanding the reasons behind its use, the current state of tolerance between patients and doctors with regard to the use of these agents can develop into a situation where these therapies become truly complementary.
